JPMorgan Chase & Co. Issues Positive Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price objective upped by JPMorgan Chase & Co. from $31.00 to $34.00 in a research report report published on Wednesday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock.

ACAD has been the topic of several other research reports. Needham & Company LLC reissued a “buy” rating and set a $34.00 price target on shares of ACADIA Pharmaceuticals in a research report on Monday, January 5th. Piper Sandler set a $37.00 target price on shares of ACADIA Pharmaceuticals in a research note on Tuesday, December 16th. Citizens Jmp raised their price target on shares of ACADIA Pharmaceuticals from $34.00 to $35.00 and gave the stock a “market outperform” rating in a report on Thursday, February 26th. Stifel Nicolaus reduced their price target on shares of ACADIA Pharmaceuticals from $25.00 to $24.00 and set a “hold” rating on the stock in a research report on Thursday, February 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $37.00 price objective on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 3rd. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, ACADIA Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $31.21.

ACADIA Pharmaceuticals Price Performance

ACAD stock opened at $23.39 on Wednesday. The business has a 50 day simple moving average of $25.23 and a 200-day simple moving average of $24.40. The firm has a market capitalization of $3.99 billion, a PE ratio of 10.21, a price-to-earnings-growth ratio of 19.00 and a beta of 0.66. ACADIA Pharmaceuticals has a 1 year low of $13.40 and a 1 year high of $28.35.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $1.48. The firm had revenue of $298.00 million for the quarter, compared to the consensus estimate of $292.54 million. ACADIA Pharmaceuticals had a return on equity of 12.49% and a net margin of 36.49%.The firm’s revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.86 earnings per share. On average, equities research analysts expect that ACADIA Pharmaceuticals will post 0.7 EPS for the current year.

Insider Transactions at ACADIA Pharmaceuticals

In other news, EVP Jennifer J. Rhodes sold 6,950 shares of ACADIA Pharmaceuticals stock in a transaction on Monday, February 9th. The stock was sold at an average price of $23.38, for a total value of $162,491.00. Following the completion of the sale, the executive vice president directly owned 7,609 shares of the company’s stock, valued at approximately $177,898.42. The trade was a 47.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 26.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Invesco Ltd. increased its stake in ACADIA Pharmaceuticals by 14.5% during the fourth quarter. Invesco Ltd. now owns 847,961 shares of the biopharmaceutical company’s stock worth $22,649,000 after purchasing an additional 107,386 shares during the period. Mercer Global Advisors Inc. ADV purchased a new position in shares of ACADIA Pharmaceuticals in the fourth quarter valued at approximately $257,000. Mackenzie Financial Corp grew its holdings in shares of ACADIA Pharmaceuticals by 7.3% in the fourth quarter. Mackenzie Financial Corp now owns 57,274 shares of the biopharmaceutical company’s stock valued at $1,526,000 after purchasing an additional 3,917 shares in the last quarter. Virtus Investment Advisers LLC increased its stake in ACADIA Pharmaceuticals by 23.1% during the 4th quarter. Virtus Investment Advisers LLC now owns 25,170 shares of the biopharmaceutical company’s stock worth $672,000 after buying an additional 4,729 shares during the period. Finally, Sphera Funds Management LTD. increased its stake in ACADIA Pharmaceuticals by 42.5% during the 4th quarter. Sphera Funds Management LTD. now owns 212,202 shares of the biopharmaceutical company’s stock worth $5,668,000 after buying an additional 63,302 shares during the period. 96.71% of the stock is currently owned by hedge funds and other institutional investors.

Key ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: JPMorgan upgraded ACAD to “overweight” and raised its price target from $31 to $34, implying substantial upside versus the current share level — a clear catalyst for buying interest. Benzinga
• Positive Sentiment: Analyst consensus remains constructive — ACAD was reported as having an average rating of “Moderate Buy,” which supports positive sentiment among institutional and retail investors. Analyst Note
• Positive Sentiment: Board addition — Acadia appointed Jonathan M. Poole to its board and audit committee, bringing experienced biopharma finance leadership that may strengthen governance and strategic financial oversight. Business Wire
• Neutral Sentiment: Short-interest reports in early March show zeros/NaN and a 0.0 days ratio — the published data appears erroneous or non-informative and should not be treated as a reliable signal without corrected filings. (Reports flagged on March 3–4.)
• Negative Sentiment: European regulatory setback — the CHMP recommended against approval of Daybue for Rett syndrome in the EU. Acadia is pursuing a CHMP re-examination, but the rejection and the resulting delay introduce regulatory risk and could push out EU revenue expectations. Zacks FiercePharma MarketWatch

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.